[HT-05] Hot Topics 05
Future prospects of drug development for neurological disorders by major pharmaceutical companies and Public Private Partnership

[HT-05-4] Recent Advances in Precision Medicine Approaches to Making Breakthrough Medicines for CNS Diseases

^○Ceri H. Davies (Takeda Pharmaceuticals Company, Japan)

神経系創薬は抗体医薬と核酸医薬のバイオ医薬による分子標的治療が実現し、新しい世代に入った。その一方でアルツハイマー病の抗体医薬の治験は第Ⅲ相での失敗が続き、神経系創薬は未だに困難な側面を内包している。 欧米ではオープンイノベーションによる創薬は50％を超え、アカデミア発のシーズから革新的バイオ医薬が実現している。日本においても急速に産学連携の創薬研究に進捗がみられるが、その一方で、日本のアカデミア発のシーズが創薬に結び付く成功確率が低いという現実がある。本シンポジウムでは、アカデミア発創薬の産官学連携の現状と展望に加えて、大手製薬会社の神経系研究開発の責任者にそれぞれの考える今後の神経系創薬の方向性について話を聞きたい。（企画：将来構想委員会）

Ceri Davies graduated from the University of Bristol with BSc (Hons) and PhD degrees in pharmacology and ran an independent academic laboratory at the University of Edinburgh before leaving academia in 1998 to join the pharmaceutical industry at Organon Laboratories Scotland and subsequently SmithKline Beecham and GlaxoSmithKline at Harlow, Verona and Singapore. He currently leads the Takeda Global Neuroscience Drug Discovery Unit from Shonan Japan. During his pharmaceutical career he has led a number of research departments and has also been the principal scientist in charge of several research programmes at preclinical and clinical phases for both psychiatric and neurodegenerative disorders. He has published over 90 full papers in peer reviewed scientific journals and has been awarded AJ Clark Scholarship and Novartis Prizes by the British Pharmacological Society in recognition of his pharmacological expertise. He has served on MRC and Wellcome Trust Grant Panels and as a visiting Honorary Professor in Neuroscience and Biomedical Systems at The University of Glasgow and is a Fellow of the British Pharmacological Society